RESUMEN
BACKGROUND: Inhaled bronchodilators are first line drugs in the treatment of chronic obstructive pulmonary disease (COPD). Tiotropium bromide is a recently introduced long-acting anticholinergic agent able to reduce dyspnoea and COPD exacerbations and to improve pulmonary function and quality of life. We designed a study to compare the short-term efficacy of tiotropium bromide with that of oxitropium bromide in improving pulmonary function in patients with COPD. METHODS: Eighty patients were randomized either to continue oxitropium 800 mcg/day or to receive tiotropium 18 mcg/day. Seventy-six (39 in the tiotropium and 37 in the oxitropium group) completed the study. Plethysmography was performed at baseline and after 72 h in all patients. The changes in functional parameters in the two groups were compared by the Mann-Whitney U-test. RESULTS: There were no differences between the two groups regarding age (72.5 vs. 74.2 years), male/female ratio (25/14 vs. 23/14) and pulmonary function at baseline. The changes in spirometric parameters were significantly greater in tiotropium- than in oxitropium-treated patients: mean forced expiratory volume in 1s (FEV(1)) increased significantly by 15% vs. 3% (P=0.017), mean FVC by 10.5% vs. 2.2% (P=0.044), and FEF 25, 50, and 75 by 34% vs. 14% (P<0.05), 33% vs. 7% (P<0.05), and 50% vs. 6% (P<0.0001), respectively; mean FRC and RV decreased nonsignificantly by 7.5% and 10% with tiotropium vs. 4.3% and 6.5% with oxitropium, respectively. CONCLUSION: The replacement of oxitropium with tiotropium significantly increases pulmonary function in patients with COPD. The improvement involves also small airways that have not been investigated thus far.
Asunto(s)
Antagonistas Colinérgicos/uso terapéutico , Pulmón/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Derivados de Escopolamina/uso terapéutico , Anciano , Broncodilatadores/uso terapéutico , Femenino , Humanos , Pulmón/efectos de los fármacos , Masculino , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Pruebas de Función Respiratoria/métodos , Bromuro de TiotropioRESUMEN
Prevention of chronic complications is very important in the management of type 2 diabetes, and the availability of a laboratory test individuating at risk subjects should have a marked usefulness. This study sought by the method of ROC curves the cut-off of glycated haemoglobin discriminating the subjects with microvascular, neurologic and renal complications from those without. The cut-off was identified at a glycated haemoglobin level of 7.95, showing a sensitivity of 74.8% and a specificity of 73.3%, which makes it a possible tool for evaluating the risk of complications in type 2 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/complicaciones , Hemoglobina Glucada/análisis , Intervalos de Confianza , Humanos , Curva ROC , Sensibilidad y EspecificidadAsunto(s)
Osteoartritis/patología , Columna Vertebral/patología , Antiinflamatorios no Esteroideos/uso terapéutico , Progresión de la Enfermedad , Humanos , Disco Intervertebral/patología , Desplazamiento del Disco Intervertebral/etiología , Desplazamiento del Disco Intervertebral/patología , Dolor de la Región Lumbar/etiología , Dolor de Cuello/etiología , Osteoartritis/diagnóstico , Osteoartritis/epidemiología , Osteoartritis/terapia , Factores de Riesgo , Osteofitosis Vertebral/etiología , Osteofitosis Vertebral/patología , Estenosis Espinal/etiología , Estenosis Espinal/patología , Columna Vertebral/cirugía , Espondiloartritis/etiología , Espondiloartritis/patología , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
PURPOSE: To determine whether a regimen of cyclosporine (CSA) and methotrexate (MTX), or CSA and hydroxychloroquine (HCQ) introduced in early rheumatoid arthritis (RA) can produce a significant improvement in clinical outcome and/or retard radiographic damage in comparison with standard monotherapy with CSA alone. METHODS: One hundred five patients with active RA of less than 36 months duration, who had never previously been treated with immunosuppressive agents, were included in a 12-month, multi-center, open, randomized trial. Patients who fulfilled the criteria for early severe RA were randomized to receive either combination therapy (CSA + MTX n = 34, CSA + HCQ n = 35) or CSA alone (n = 36). RESULTS: CSA + MTX was more effective than the other two treatment groups in controlling RA symptoms. CSA+MTX did not show a significant radiographic progression according to Larsen-Dale (0.90 +/- 3.89 compared to baseline values, P > 0.05); moreover, patients treated with CSA alone or CSA+HCQ showed a significant worsening of Larsen-Dale score (2.91 +/- 5.99 and 2.97 +/- 4.28 respectively vs baseline values, P < 0.05), although not significant when compared with the CSA + HCQ group (P = 0.56 and 0.39, respectively). CONCLUSIONS: This trial indicated that CSA+MTX was more effective than the other two treatments in improving clinical data and inhibiting radiographic progression, although the differences were not significant in this relatively small study. However, the difference was significant in favor of CSA + MTX regarding ACR 50% response.